Teva Pharmaceuticals has recalled lot 31329657B of IDArubicin Hydrochloride Injection USP 5mg/5mL vials. An internal inspection found one vial contained silica and iron oxide particulate matter. According to Teva, this defect has not been observed in other vials as of the recall date.

• There is no member impact through Benecard Central.
• IDArubicin Hydrochloride Injection USP is used in combination with other FDA-approved anti- leukemic drugs to treat acute myeloid leukemia in adults. Administering an injectable that contains particulate matter can have consequences ranging from local irritation to fatal blood vessel However, Teva has determined the chance of harm to patients from the recalled lot is remote or unlikely.
• Teva advises consumers who have questions or concerns about the recalled medication to first consult with their healthcare provider. To contact Teva with medical-related questions or to report an adverse event, consumers can call Teva Medical Information at 1-888-838-2872 (option 3, then option 4) or email druginfo@tevapharm.com. For questions related to product quality complaints, consumers can call Teva Quality Assurance Services at 1-888-838-2872 (option 4).
• The FDA has published a copy of the complete recall notice on its website.